A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine ​supply and ...

(Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some ...

The FDA granted emergency use authorization (EUA) for an updated Novavax COVID-19 vaccine to protect against hospitalization and death from circulating variants. The protein-based shot represents a ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Novavax's business has improved over the past 18 months. The company has several important catalysts and potential growth drivers. The biotech remains a relatively risky stock pick. However, a lot has ...

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant ...

In the latest close session, Novavax (NVAX) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...